Pila Pharma

Malmö-based Pila Pharma intends to participate in the development of the drug candidate XEN-D0501. The candidate has an anti-inflammatory effect, which in turn stimulates both insulin production and insulin sensitivity, both of which are crucial in diabetes.

The candidate may also have both an appetite-suppressing and metabolic effect, and is thus expected to be used to reduce weight. In turn, improved weight control leads to fewer obesity-related sequelae such as diabetes and cardiovascular disease.

By providing an effective obesity-regulating drug, Pila Pharma believes it has a good chance of becoming part of the solution to the enormous health challenges posed by obesity and diabetes, and thereby participating in a rapidly growing market.